Stock Market Summary – November 20, 2025

The stock market experienced a significant reversal yesterday, as shares that began the day strong ended it with losses. This was driven largely by companies associated with data-center expenditure. The most notable gainer was Corning, with 50 more shares purchased at approximately $78 each by Jim Cramer’s Charitable Trust, resulting in its total owned shares increasing to 650. On the flip side, significant losses were noted in Nvidia which peaked at $196, corresponding to roughly a 5% gain, before closing the day down by 2%.

Consumer behavior has leaned towards saving more as evidenced by the strong sales growth in value retailers, Walmart and T.J. Maxx, that raised their annual forecasts as the holiday season began. Correspondingly, the shares of both Walmart and T.J. Maxx saw upward movement, despite the major US stock indices declining.

In terms of predictions, despite a higher-than-expected increase in jobs added in September (119,000 versus the forecasted 50,000), the unemployment rate increased which reduced the perceived likelihood of a December rate cut from 98.8% a month ago to 40% recently. Key stock behaviors to watch include Nvidia, Exact Sciences, Walmart, Strategy, and Regeneron.

Bitcoin fell to its lowest level since April, standing at $86,690.11, a significant downturn influenced by investor retreat from riskier assets and ongoing consideration of another Federal Reserve rate cut. Ethereum also faced a similar decline of over 3% to settle below the $3000 mark.

Companies adversely affected in yesterday’s trading include Nvidia, Palantir Technologies, AMD, Super Micro Computer, Strategy, Robinhood Markets, Coinbase, and Circle Internet with significant losses up to 9%. Other companies such as Exact Sciences, Regeneron, and Walmart fared better with share price increment of up to approximately 17%.

Significant announcements yesterday included Abbott Laboratories’ decision to acquire cancer test provider Exact Sciences for $21 billion, healthcare company Solventum’s decision to acquire Acera Surgical for $725 million in cash, and Bath & Body Works’ disappointing third-quarter earnings prompting a 25% decline in its stock price.